Gefitinib Intermediate CAS 199327-61-2 Maʻemaʻe >99.0% (HPLC)
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui o 7-Methoxy-6-(3-Morpholin-4-ylpropoxy) quinazolin-4 (3H) -One (CAS: 199327-61-2) me ke kūlana kiʻekiʻe, waena. o Gefitinib (CAS: 184475-35-2).Hiki iā Ruifu Chemical ke hāʻawi aku i ka honua holoʻokoʻa, ke kumukūʻai hoʻokūkū, ka lawelawe maikaʻi loa, ka liʻiliʻi a me ka nui nui i loaʻa.E kūʻai aku i nā Intermediates Gefitinib,Please contact: alvin@ruifuchem.com
| Inoa Kimia | 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-Hoʻokahi |
| Nā huaʻōlelo like | 7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4(3H)-Hoʻokahi;7-Methoxy-6-[3-(4-Morpholinyl)propoxy]-4(3H)-Quinazolinone;7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-One |
| haumia | Gefitinib haumia 5;ʻO Gefitinib EP ʻO ka haumia A |
| Kūlana Kūʻai | Ma ke Kahua, Hana Hana Kūʻai |
| Helu CAS | 199327-61-2 |
| ʻĀpana Molekala | C16H21N3O4 |
| Kaumaha Molecular | 319.36 g/mol |
| Lae hehee | 242.0~247.0 ℃ |
| ʻO ka mānoanoa | 1.32±0.10 g/cm3 |
| COA & MSDS | Loaʻa |
| Ke kumu | Shanghai, Kina |
| Brand | Kemika Ruifu |
| Nā mea | Nā Kūlana Nānā | Nā hualoaʻa |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo | Hoʻokō |
| Lae hehee | 242.0~247.0 ℃ | 243.6~244.5 ℃ |
| Nalo ma ka maloo | <0.50% | 0.15% |
| Koena ma ka Ignition | <0.20% | 0.11% |
| Hoʻokahi haumia | <0.50% | <0.30% |
| Huina paumaele | <1.00% | 0.30% |
| Maʻemaʻe / Kaʻina Hanana | >99.0% (HPLC) | 99.7% |
| 1H NMR Spectrum | Kūlike me ka Hoʻolālā | Hoʻokō |
| Ka hopena | Ua hoʻāʻo ʻia ka huahana a hoʻokō me nā kikoʻī i hāʻawi ʻia | |
| Palapala noi | Kūwaena o Gefitinib (CAS: 184475-35-2) | |
Pūʻolo:ʻO ka ʻōmole Fluorinated, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E hoʻopaʻa paʻa i ka pahu a mālama i loko o kahi hale kūʻai maloʻo a maloʻo (2 ~ 8 ℃) a me kahi hale kūʻai maikaʻi mai nā mea like ʻole.E pale i ka malamalama a me ka wai.
Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.
Pehea e kūʻai ai?E ʻoluʻolu e kelepona maiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 mau makahiki ʻike?Loaʻa iā mākou ma mua o 15 mau makahiki o ka ʻike i ka hana ʻana a me ka hoʻokuʻu ʻana aku i kahi ākea ākea o nā intermediates pharmaceutical kiʻekiʻe a i ʻole nā kemika maikaʻi.
Mākeke Nui?E kūʻai aku i ka mākeke kūloko, ʻAmelika ʻĀkau, ʻEulopa, India, Korea, Iapana, Australia, etc.
Nā pono?ʻO ke kūlana kiʻekiʻe, ke kumukūʻai kūpono, nā lawelawe ʻoihana a me ke kākoʻo ʻenehana, ka lawe wikiwiki ʻana.
ʻAno maikaʻiHōʻoiaʻiʻo?Pūnaehana hoʻomalu maikaʻi koʻikoʻi.ʻO nā lako ʻoihana no ka nānā ʻana ʻo NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Nā laʻana?Hāʻawi ka hapa nui o nā huahana i nā laʻana manuahi no ka loiloi maikaʻi, pono e uku ʻia ke kumukūʻai e nā mea kūʻai aku.
Hooia Hale Hana?Welina mai ka loiloi hale hana.E ʻoluʻolu e hoʻopaʻa manawa ma mua.
MOQ?ʻAʻohe MOQ.ʻAe ʻia ke kauoha liʻiliʻi.
Manawa Hoʻouna? Inā i loko o ka waihona, ʻekolu lā hoʻouna ʻia.
Kaʻahele?Ma ka Express (FedEx, DHL), ma ka Air, ma ke Kai.
Nā palapala?Ma hope o ka lawelawe kūʻai: COA, MOA, ROS, MSDS, etc.
Hoʻohui Kuʻuna?Hiki ke hāʻawi i nā lawelawe synthesis maʻamau e kūpono i kāu mau pono noiʻi.
Kūkākūkā uku?E hoʻouna mua ʻia ka invoice Proforma ma hope o ka hōʻoia ʻana o ke kauoha, hoʻopili ʻia kā mākou ʻike panakō.Uku e T/T (Telex Transfer), PayPal, Western Union, etc.
7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-One (CAS: 199327-61-2) he mea waena / haumia o Gefitinib (CAS: 184475-35-2).ʻO Gefitinib kahi lāʻau lapaʻau anti-tumor i hoʻolālā ʻia e AstraZeneca, UK.ʻO Gefitinib ka lāʻau lapaʻau mua i hoʻopaʻa ʻia no ka mālama ʻana i ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi.Hana ia ma ke kaohi ʻana i ke ala transduction hōʻailona o ka epidermal growth factor receptor tyrosine kinase (EGFR-TK).I ʻAukake 2002, ua kūʻai mua ʻia ʻo Gefitinib ma Iapana ma ke ʻano he lāʻau lapaʻau mua no ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi ma lalo o ka inoa kālepa ʻo Iressa.I Mei 2003, ua ʻae ka US Food and Drug Administration iā Gefitinib i ke kolu o ka lālani monotherapy no nā poʻe maʻi me ka maʻi maʻi ʻaʻa ʻole liʻiliʻi liʻiliʻi i hiki ʻole ke hoʻohana i nā lāʻau anticancer e pili ana i ka platinum a me ka docetaxel chemotherapy.I kēia manawa, ua ʻae ʻia ʻo Gefitinib e Australia, Iapana, Argentina, Singapore a me South Korea no ka mālama ʻana i ka maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi.Ma ka lā 28 o Pepeluali, 2005, ua ʻae ka China Food and Drug Administration i ka Gefitinib no ka mālama ʻana i ka maʻi maʻi maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi kūloko (NSCLC) i loaʻa mua i ka chemotherapy.ʻAʻole ʻae ʻia i kēia manawa no ka hoʻohana ʻana i ka lāʻau lapaʻau mua no ka NSCLC kiʻekiʻe.Ma Iulai 1, 2009, ua ʻae ka European Medicines Agency iā Gefitinib no ka lālani mua, laina ʻelua a me ke kolu o ka lāʻau lapaʻau o ka maʻi maʻi maʻi ʻaʻai kūloko a i ʻole metastatic liʻiliʻi liʻiliʻi me ka EGFR gene mutations i nā pākeke.
